drug
(ertugliflozin + sitagliptin phosphate)
Marketedupdated 3mo agoby Merck Sharp & Dohme (IA) LLC
Approvedcommunity read0 votes
indications
investigational
Type 2 Diabetes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 24, 2026
119 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Oct 21, 2030formulationUS 93082044.2y
- Oct 21, 2030formulationUS 93082044.2y
- Oct 21, 2030method-of-use (U-2214)US 94399014.2y
- Oct 21, 2030method-of-use (U-2214)US 94399014.2y
- Jul 13, 2030compositionUS 80805804.0y
- Jul 13, 2030compositionUS 80805804.0y
- May 24, 2027patentUS 7326708*PED300d
- May 24, 2027patentUS 7326708*PED300d
- Nov 24, 2026compositionUS 7326708119d
- Nov 24, 2026compositionUS 7326708119d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 46m ago
Found something off?
comments(0)
5-min edit window · permanent after that